A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

被引：2

作者：

Nakamura, Nobuhiko ^{[1
]}

Kasahara, Senji ^{[2
]}

Kitagawa, Junichi ^{[2
]}

Nakamura, Hiroshi ^{[1
]}

Sawada, Michio ^{[3
]}

Fukuno, Kenji ^{[4
]}

Shibata, Yuhei ^{[2
]}

Kaneda, Yuto ^{[4
]}

Hara, Takeshi ^{[5
]}

Kanemura, Nobuhiro ^{[1
]}

Tsurumi, Hisashi ^{[1
,5
]}

Shimizu, Masahito ^{[1
]}

机构：

[1] Gifu Univ Hosp, Dept Hematol & Infect Dis, 1-1 Yanagido, Gifu 5011194, Japan

[2] Gifu Municipal Hosp, Dept Hematol, Gifu, Japan

[3] Gifu Red Cross Hosp, Dept Hematol, Gifu, Japan

[4] Takayama Red Cross Hosp, Dept Hematol, Gifu, Japan

[5] Matsunami Gen Hosp, Dept Hematol, Gifu, Japan

来源：

EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2022年 / 11卷 / 01期

关键词：

Follicular lymphoma; Mantle cell lymphoma; Bendamustine; Rituximab; Cytarabine; PLUS RITUXIMAB; INDOLENT;

D O I：

10.1186/s40164-022-00264-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of 4 cycles (range 2-6) of BRAC. The complete response rate was 61.5%, and the overall response rate was 84.6%; the 2-year overall survival was 76.9%, and the 2-year progression-free survival was 69.2%. Although all patients received G-CSF prophylaxis, grade 3 or higher neutropenia was observed in all cycles, and the incidence of febrile neutropenia was 20%. Grade 4 thrombocytopenia was observed in 92.5% of all cycles, and platelet transfusion was performed in 94%. Although hematological toxicity was relatively high, BRAC therapy was effective for relapsed and refractory FL or MCL. Further studies are needed to determine the optimal dose of BRAC therapy.

引用

页数：4

共 12 条

[1] Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide [J].

Albertsson-Lindblad, Alexandra ;

Freiburghaus, Catja ;

Jerkeman, Mats ;

Ek, Sara .

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)

[2] Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines [J].

Castegnaro, Silvia ;

Visco, Carlo ;

Chieregato, Katia ;

Bernardi, Martina ;

Albiero, Elena ;

Zanon, Cristina ;

Madeo, Domenico ;

Rodeghiero, Francesco .

LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2262-2268

[3] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[4] Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies [J].

Hanel, Walter ;

Epperla, Narendranath .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)

[5] High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy [J].

Hirayama, Alexandre V. ;

Gauthier, Jordan ;

Hay, Kevin A. ;

Voutsinas, Jenna M. ;

Wu, Qian ;

Pender, Barbara S. ;

Hawkins, Reed M. ;

Vakil, Aesha ;

Steinmetz, Rachel N. ;

Riddell, Stanley R. ;

Maloney, David G. ;

Turtle, Cameron J. .

BLOOD, 2019, 134 (07) :636-640

[6] Mantle cell lymphoma and its management: where are we now? [J].

Ladha, Abdullah ;

Zhao, Jianzhi ;

Epner, Elliot M. ;

Pu, Jeffrey J. .

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)

[7] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma [J].

Robinson, K. Sue ;

Williams, Michael E. ;

van der Jagt, Richard H. ;

Cohen, Philip ;

Herst, Jordan A. ;

Tulpule, Anil ;

Schwartzberg, Lee S. ;

Lemieux, Bernard ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) :4473-4479

[8] Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial [J].

Rummel, Mathias ;

Kaiser, Ulrich ;

Balser, Christina ;

Stauch, Martina ;

Brugger, Wolfram ;

Welslau, Manfred ;

Niederle, Norbert ;

Losem, Christoph ;

Boeck, Hans-Peter ;

Weidmann, Eckhart ;

von Gruenhagen, Ulrich ;

Mueller, Lothar ;

Sandherr, Michael ;

Hahn, Lars ;

Vereshchagina, Julia ;

Kauff, Frank ;

Blau, Wolfgang ;

Hinke, Axel ;

Barth, Juergen .

LANCET ONCOLOGY, 2016, 17 (01) :57-66

[9] The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J].

Swerdlow, Steven H. ;

Campo, Elias ;

Pileri, Stefano A. ;

Harris, Nancy Lee ;

Stein, Harald ;

Siebert, Reiner ;

Advani, Ranjana ;

Ghielmini, Michele ;

Salles, Gilles A. ;

Zelenetz, Andrew D. ;

Jaffe, Elaine S. .

BLOOD, 2016, 127 (20) :2375-2390

[10] Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi [J].

Visco, Carlo ;

Chiappella, Annalisa ;

Nassi, Luca ;

Patti, Caterina ;

Ferrero, Simone ;

Barbero, Daniela ;

Evangelista, Andrea ;

Spina, Michele ;

Molinari, Annalia ;

Rigacci, Luigi ;

Tani, Monica ;

Di Rocco, Alice ;

Pinotti, Graziella ;

Fabbri, Alberto ;

Zambello, Renato ;

Finotto, Silvia ;

Gotti, Manuel ;

Carella, Angelo M. ;

Salvi, Flavia ;

Pileri, Stefano A. ;

Ladetto, Marco ;

Ciccone, Giovannino ;

Gaidano, Gianluca ;

Ruggeri, Marco ;

Martelli, Maurizio ;

Vitolo, Umberto .

LANCET HAEMATOLOGY, 2017, 4 (01) :E15-E23

← 1 2 →